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Solid pharmaceutical preparations can be con-
sidered as heterogeneous systems consisting of one
or more active pharmaceutical ingredients (APIs)
and several excipients. In such blends physical inter-
actions are quite common. Some of them are delib-
erately invoked to produce a certain effect, for
example, to aid processing, modify drug dissolution
(oral modified release) or distribution in the body
(parenteral modified release drugs). Other interac-
tions in solid phase are unintended, usually causing
the problems. The essence of physical interactions is
that interacting molecules are not modified in any
way. In the other words: new molecules, in chemical
meaning, are not created.
Most poly active component drugs, currently
available on the market, belong to the group of non-
steroidal anti-inflammatory drugs (NSAIDs); a drug
class also comprising combinations of antipyretics
and/or analgesics (e.g., ibuprofen (IBU)) together
with APIs from other pharmacological groups as
antiallergics, sympathomimetics and antitussives.
The physical interactions between active ingredients
are rare. Considering ibuprofen for example, only
few reports concerning incompatibilities with keto-
profen (1) and menthol (2, 3) were found. Much
more publications are dealing with excipients.
Magnesium stearate is commonly used in pharma-
ceutical manufacturing as a ìflow agentî which
helps ensure that the pressing process is smooth and
the ingredients stay blended in the proper propor-
tions. It was demonstrated (4) that the particles of
magnesium stearate appear to adhere to the surfaces
of the other components on mixing. All stearates
were found to form simple eutectics with ibuprofen
(5-9). Some interaction were also observed with
polyvinylpyrrolidone (PVP) and calcium phosphate
(8, 9). For other drugs new associative structures (8,
10) were reported when a surfactant, sodium dode-
cylsulfate, was added as well as interactions of lac-
tose with drugs containing amino groups (11).
In our previous paper (12) we have discussed
the use of DSC method in quantification of APIs in
commercially available, one-component tablets. For
this purpose, a relationship between the signal value
of analyte (enthalpy change ∆H) and its concentra-
tion in the matrix was exploited. The scale of the
problem was showed using commercially available
different tablets of paracetamol (PAR). In the course
of the studies it was shown that composition of the
mixtures (in a meaning of used excipients), the way
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of their preparation (as non-micronized mixture,
micronized mixture or pure raw analyte) and the
weights of samples alter the final results of such
measurements leading to different contents of PAR.
It was also shown that there is no apparent direction
of the observed differences, suggesting that the use
of the DSC method for quantification of APIs in
commercially available tablets should be assessed
individually and requires appropriate empirical pre-
liminary studies in each case.
The objective of the present study was to esti-
mate the influence of interactions between two
active agents, presented in the tablet, on their quan-
tification. For that reason six commercially avail-
able tablets with IBU different in weight, type of
excipients and composition, were determined by
DSC method. Two calibration curves plotted from
mixtures containing micronized and non-micronized
starch (Starch 1500) with an increasing amounts of
IBU were used. The micronization process was
applied to modify the crystalline nature of mixtures
under study. In this way the complex technological
processes of their manufacturing were emulated.
Appropriate calibration curves were further applied
to calculate the final experimental contents of IBU
(ODSC) in the tablets and were compared with those
declared (D) by the manufacturer using equation
A(%) = [(ODSC-D)/D]◊100.
EXPERIMENTAL
Materials
Ibuprofen powder ñ pure polymorphic form I
with estimated melting temperature at Tonset = 76.1OC
was obtained from Hubei Granules-Biocause
Pharmaceutical Co., Ltd., China (LOT 400-
0709065M). The corn starch Starch 1500 was from
Colcorcon Ltd. UK (Lot 500075).
Ibuprofen is a low potency, high dose drug.
Typical dose of IBU in one component drugs in
Poland is 400 mg, however in two component drugs
the dose does not exceed 200 mg.
The following two components tablets contain-
ing 200 mg of IBU per tablet and PAR were used:
Metafen (325 mg of PAR) manufactured by
Polpharma, Poland (LOT 016582), the mean weight
of tablet 699.20 mg, composed of povidone, prege-
latinized starch, microcrystalline cellulose, magne-
sium stearate; Nurofen Ultima (500 mg of PAR)
manufactured by Reckitt Benckiser, Poland (LOT
AB070), the mean weight of tablet 870.38 mg, com-
posed of croscarmellose sodium, microcrystalline
cellulose, anhydrous colloidal silica, magnesium
stearate, stearic acid.
The following two components tablets contain-
ing 200 mg of IBU and 30 mg of pseudoephedrine
hydrochloride were used: Acatar Zatoki manufac-
tured by US Pharmacia Ltd., Poland (LOT
U1107221), the mean weight of tablet 530.36 mg,
composed of cellulose (Elcema P-100 and Elcema
F-150), corn starch, pregelatinized starch, Guar
gum, talc, croscarmellose sodium, crospovidone,
colloidal silica, hydrogenated vegetable oil;
Ibuprom Zatoki manufactured by US Pharmacia
Ltd., Poland (LOT U1205401), the mean weight of
tablet 544.08 mg, composed of cellulose (Elcema P-
100 and Elcema F-150), corn starch, pregelatinized
starch, Guar gum, talc, croscarmellose sodium,
crospovidone, colloidal silica, hydrogenated veg-
etable oil; Modafen manufactured by Zentiva,
Czech Republic (LOT 3230912), the mean weight
of tablet 575.18 mg, composed of microcrystalline
cellulose, lactose monohydrate, corn starch, pregela-
tinized starch, sodium lauryl sulfate, povidone 25,
stearic acid, sodium carboxymethyl starch, anhy-
drous colloidal silica; Nurofen Zatoki manufactured
by Reckitt Benckiser, Poland (LOT AH006), the
mean weight of tablet 374.22 mg, composed of cal-
cium phosphate, microcrystalline cellulose, povi-
done, croscarmellose sodium, magnesium stearate.
Sample preparation
Twenty tablets of each medical product under
the study were individually weighed and ground in
an agate mortar and pestle into fine powder.
The set of IBU mixtures with starch Starch
1500 (1000 mg each) at concentrations from 10% to
60% (corresponding to 0.50-3.0 mg of drug in the
sample) were separately prepared, gently homoge-
nized and divided. One part (500 mg) of received
physical (non-micronized) mixture was ready for
further experiments; the other was micronized in an
agate mortar and pestle with some drops of
methanol for 10 min.
Method
The principle of the method is a relationship
between the signal value of IBU (enthalpy change
∆H) and its concentration in the matrix. For this pur-
pose both of micronized and non-micronized sets of
mixtures were measured by means of DSC. In this
way two calibration curves with an increasing
amounts of IBU were plotted. Appropriate calibra-
tion curves were further applied to calculate the 
final experimental contents of IBU (ODSC) in the
tablets and were compared with those declared (D)
by the manufacturer using equation A(%) =
[(ODSC-D)/D]◊100.
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Thermal analysis
The DSC measurements were performed in
nitrogen atmosphere with a flow rate of 50 mL/min
using EXSTAR DSC 7020 apparatus (SII Nano-
Technology Inc.) calibrated with indium and tin, and
equipped with DSC7020 electric cooling unit.
The samples of micronized and non-micro-
nized mixtures of about 5.0 mg were accurately
weighed in aluminium pans and sealed. The pans
were equilibrated at 30OC for 15 min and thereafter
the melting behavior was analyzed at heating rate of
10OC/min. All measurements were performed at
least three times and averaged. The tablets were
examined at least six times.
Validation of DSC method
The method was validated for specificity, lin-
earity, precision, limit of detection, and limit of
quantification as well (13). The calculations 
were made using statistical program STATISTICA
v.10.
Specificity
Specificity of the method was assessed by
comparing the DSC heating traces of raw IBU, raw
excipients and obtained both micronized and
non-micronized mixtures. The Tonset, Tmax tempera-
tures, and presence of new chemical individuals
were taken into account.
Linearity
The calibration plots were constructed by analy-
sis of seven (n = 7) different mixtures (both micronized
and non-micronized), corresponding to content of IBU
ranging from 0.50 mg to 3.00 mg. Determination of
linearity was made via three replicates and assessed as
Table 1. Effects of mixture composition on the area of melting peak ∆H (averaged from three determinations). The differences between
∆H of IBU of non micronized and micronized mixtures (B) as a function of IBU concentration in the sample shows linear dependence: y
= 41.27-19.98◊X, r = 0.9976, r2 = 0.9952.
Composition of Content of IBU
∆H of IBU* [mJ/mg] 
in the samplethe mixture
[mg] 
Micronized Non micronized
B** [mJ/mg]
mixtures mixtures
0.50 53.38 83.00 29.62
1.00 130.50 153.00 22.50
1.50 208.50 219.75 11.25
IBU/starch 1.75 241.5 249.08 7.58
2.00 293.33 295.50 2.17
2.50 370.00 360.00 -10.00
3.00 435.00 416.00 -19.00
*∆H was recalculated to the content of IBU in the sample; **differences between ∆H of non micronized and micronized mixtures
Table 2. Data validation of DSC method. 
Validation parameters Micronized mixtures Non-micronized mixtures
Specificity Specific Specific
Slope (a ± Sa) 154.94 ± 2.74 134.96 ± 2.68
Intercept (b ± Sb) -23.68 ± 5.27 17.59 ± 5.15
r 0.9992 0.9990
r2 0.9984 0.9980
LOD [mg] 0.12 0.14
LOQ [mg] 0.37 0.41
Linearity [mg] 0.37 ñ 3.00 0.41 ñ 4.41
Precision (n = 6)            %RSD 1.95 2.07
Regression equation y = ax + b; Sa - standard deviation of slope; Sb - standard deviation of intercept.
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a relationship between the area of DSC melting peak
∆H and content of IBU in mg per sample. 
Linearity was reported as the linear calibration
equations (y = ax + b) and the correlation coeffi-
cients r and r2.
Limits of detection (LOD) and quantification (LOQ)
LOD and LOQ were calculated from the cali-
bration curve slope (a) and the slope standard esti-
mation error (Se), using formulas: LOD = 3.3 ◊ Se/a
and LOQ = 10 ◊ Se/a.
Precision
The repeatability of the method was deter-
mined by analysis of six (n = 6) replicates of sam-
ples from individual weighing. The study was done
for one concentration level of 2.00 mg of IBU in the
sample, and the results were expressed as the rela-
tive standard deviation (%RSD).
RESULTS AND DISCUSSION
The determined enthalpy changes ∆H of mix-
tures with increasing IBU contents (0.5 mg to 3.00
mg per sample giving the concentration from 10 to
60%) and starch, both micronized and non-micro-
nized, are presented in Table 1.
One can see the differences between ∆H values.
Within the range from 0.50 mg to 2.00 mg of IBU per
sample (10 to 40%) the ∆H values of micronized mix-
tures were distinctly lower than corresponding
non-micronized mixtures. For contents of IBU over
2.00 mg per sample (40%) the relationship was
reversed and the micronized mixtures enthalpies were
distinctly higher. Interestingly, the ∆H differences
(labeled as B in Table 1) and concentration of IBU are
linearly correlated with strong regression coefficient r
= 0.9976 and r2 = 0.9952 (y = 41.27 - 19.98 ◊ X). At
this point we canít comment this phenomenon.
In order to plot appropriate calibration curves,
the obtained ∆H enthalpies of micronized as well as
non-micronized mixtures as a function of the
increasing weights of IBU in a constant sample
weight (5.0 mg) were used. The validation data were
summarized in Table 2. It thus demonstrated that
developed method meets the acceptance criteria in
the scope of specificity, sensitivity, linearity and
precision.
Table 3 shows the melting onset and maximum
temperatures (Tonset, Tmax) of ibuprofen in tablets
under study. With two exceptions (Metafen and
Nurofen Ultima), the temperatures are comparable
to pure raw IBU and ranging from 75.9OC to 76.2OC
and 76.0OC to 76.2OC for Tonset and Tmax, respective-
ly. Metafen and Nurofen Ultima have significantly
lower temperatures: 72.9OC, 76.8OC and 70.9OC,
75.4OC. It is interesting that they are both composed
of IBU in the presence of paracetamol (PAR) and
the concentrations of IBU per tablet are definitely
lower than 29% and 23% while for the others are
ranging from 34.77% to 53.43%.
The calculated calibration curves described
above were applied to quantitative determinations of
IBU. The final experimental contents ODSC ± SD and
A(%) are presented in Table 4.
For clarity of observation, all respective drugs
under study were gathered in Table 5, to show which
excipients could interfere with IBU. Components of
particular importance were marked in the gray
fields.
The content of IBU in presence of pseu-
doephedrine hydrochloride, in tablets (Acatar Zatoki
and Ibuprom Zatoki) composed from starch, cellu-
lose, croscarmellose sodium, colloidal silica, Guar
gum, talc, crospovidone and hydrogenated veg-
etable oil were very close to those declared by the
manufacturer. It suggests that there are no interac-
tions between drug components and if they are, they
Table 3. The melting temperatures Tonset and Tmax, enthalpy change ∆H and content of ibuprofen (IBU) in poly pharmaceutical drugs under
study.
Analgesic Tonset [OC] Tmax [OC] ∆H [mJ/mg] % IBU/tablet
Metafen 72.9 76.8 94.98 28.60
Nurofen Ultima 70.9 75.4 98.02 22.98
Acatar Zatoki 76.2 79.0 146.25 37.73
Ibuprom Zatoki 76.1 79.1 139.25 36.78
Modafen 75.9 79.2 130.50 34.77
Nurofen Zatoki 76.0 79.0 118.75 53.43
Pure Ibuprofen 76.1 79.0 130.00 -
Table 5. The components of drugs under study. The presence of the ingredient in the drug was marked with "◊"; respective excipients that
could interfere with IBU are in the gray fields.
Drug name Type of excipient
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Metafen ◊ ◊ ◊ ◊
Nurofen U. ◊ ◊ ◊ ◊ ◊
Acatar Z. ◊ ◊ ◊ ◊ ◊ ◊ ◊ ◊
Ibuprom Z. ◊ ◊ ◊ ◊ ◊ ◊ ◊
Modafen ◊ ◊ ◊ ◊ ◊ ◊ ◊
Nurofen Z. ◊ ◊ ◊ ◊ ◊
1-povidone (PVP); 2-starch; 3-cellulose; 4-magnesium stearate; 5-croscarmellose sodium; 6-colloidal silica; 7-stearic acid; 8-Guar gum;
9-talc; 10-crospovidone; 11-hydrogenated vegetable oil; 12-calcium phosphate; 13-sodium lauryl sulfate; 14-lactose.
Table 4. Quantification of IBU in tablets under study by means of DSC method, based on calibration curves
obtained from micronized and non micronized mixtures. 
IBU content
Analgesic (ODSC) ± SD A(%)
[mg/tablet] [(ODSC-D)/D]x100
Micronized mixtures
Metafen 143.95 ± 5.43 -28.02
Nurofen Ultima 153.25 ± 1.44 -23.38
Acatar Zatoki 205.44 ± 1.24 2.72
Ibuprom Zatoki 196.58 ± 4.27 -1.71
Modafen 186.17 ± 3.08 -6.91
Nurofen Zatoki 164.60 ± 4.26 -17.70        
Non micronized mixtures
Metafen 122.50 ± 6.24 -38.75
Nurofen Ultima 122.70 ± 1.65 -38.65
Acatar Zatoki 203.42 ± 1.42 1.71
Ibuprom Zatoki 192.40 ± 4.90 -3.80
Modafen 178.56 ± 3.53 -10.72
Nurofen Zatoki 166.08 ± 5.32 -16.96
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donít affect the final result. In other tablets consist-
ing of pseudoephedrine hydrochloride the effect of
stearates and PVP (Nurofen Zatoki, Modafen), cal-
cium phosphate (Nurofen Zatoki), surfactans (sodi-
um lauryl sulfate) as well as lactose (Modafen) were
leading to moderate interactions. The strongest
interactions can be observed for tablets composed
from IBU in the presence of PAR where magnesium
stearate, stearates and PVP were found.
CONCLUSIONS
The substances found in tablets often interact
between themselves. The manufacturers generally
provide an information on the type of excipients
used during their production, however, usually only
for main components and in most cases, there are no
data concerning their concentrations. For that rea-
son, it is difficult to estimate the influence of solid
phase interactions on quantitative measurements.
However, some general remarks are possible. The
calculated statistical parameters of DSC method
show that with several limitations it is possible to
quantify API in poly pharmaceutical tablets. Under
conditions that were used in the research, it was
found that some excipients such as stearates, povi-
done, sodium lauryl sulfate as well as lactose could
modify the measurement results in various ways. On
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the other hand, the second active ingredient (both
PAR and pseudoephedrine hydrochloride) doesnít
seem to interfere. It should be emphasized that the
described mutual solid state interactions can be
observed during DSC measurements, while they do
not change the quality of drug, they can sometimes
alter the drug pharmacodynamics.
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